DWA
ORIC icon

Dorsey Wright & Associates’s Oric Pharmaceuticals ORIC Stock Holding History

Dorsey Wright & Associates’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-2,513
Closed -$15.2K – 246
2023
Q3 		$15.2K Buy
+2,513
New +$20.6K ﹤0.01% 281

Other funds holding ORIC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return
CG
Column Group San Francisco, California $88.1M AUM 148.03% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

Dorsey Wright & Associates's ORIC Position: Q4 2023 in Review

Dorsey Wright & Associates sold out of Oric Pharmaceuticals (ORIC) in Q4 2023, closing a stake of 2,513 shares — an estimated $15.2K sold.

Dorsey Wright & Associates first reported a position in ORIC in Q3 2023 and held it in 1 quarter. The position peaked at $15.2K in Q3 2023. 92 funds tracked by Wall St. Rank hold ORIC as of Q4 2023.

  • Dorsey Wright & Associates reported no remaining Oric Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Dorsey Wright & Associates sold 2,513 Oric Pharmaceuticals shares in Q4 2023, an estimated $15.2K.
  • Dorsey Wright & Associates first reported a position in Oric Pharmaceuticals in Q3 2023 and held it in 1 quarter.
  • Dorsey Wright & Associates's Oric Pharmaceuticals position peaked at $15.2K in Q3 2023.
  • 92 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q4 2023.

Based on Dorsey Wright & Associates's 13F filing for Q4 2023, filed 13 Feb 2024.